Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M

Natera, Inc.

2025-Q1 EPS reported -$0.50 revenue$501,830,000

Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).
Gross margin 63.1% (up from 56.7%); tests processed 855,100 (+16.2%).
Net loss $66.9M ($0.50 EPS) improved from $67.6M ($0.56) in prior year.
Positive operating cash flow $23.2M; cash & investments $991.6M.
Oncology test volume 167,700 (+46.1% YoY); CEO cites record Signatera growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.